Edgewise's EDG-7500 Mechanism Lends Confidence, RBC Says

MT Newswires Live09-23 23:41

Edgewise Therapeutics' (EWTX) EDG-7500 mechanism reveal accounts for strong clinical showing, lending confidence ahead of phase 3 trial design, RBC said in a Tuesday note.

Earlier, the company unveiled a differentiated mechanism of action of its cardiac sarcomere modulator EDG-7500.

The mechanism that targets the Regulatory Light Chain has shown in preclinical models to improve cardiac relaxation while preserving systolic function and cardiac reserve, Edgewise said.

"We think the mechanism makes sense of the differentiated clinical profile to date," RBC analysts said.

"While the stock is unlikely to move significantly today, we came away confident in EWTX's opportunity to differentiate in HCM from CMIs," they added. HCM refers to hypertrophic cardiomyopathy, and CMI to cardiac myosin inhibitors.

RBC maintained its outperform rating and $59 price target.

Price: 41.26, Change: -3.25, Percent Change: -7.30

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2669876844?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-23 23:41","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2669876844","market":"fut","top_or_hot":-1,"title":"Edgewise's EDG-7500 Mechanism Lends Confidence, RBC Says","media":"MT Newswires Live","content":"<html><body><p> Edgewise <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>' (EWTX) EDG-7500 mechanism reveal accounts for strong clinical showing, lending confidence ahead  of phase 3 trial design, RBC said in a Tuesday note.</p><p>Earlier, the company unveiled a differentiated mechanism of action of its cardiac sarcomere modulator EDG-7500.</p><p>The mechanism that targets the Regulatory Light Chain has shown in preclinical models to improve cardiac relaxation while preserving systolic function and cardiac reserve, Edgewise said.</p><p>\"We think the mechanism makes sense of the differentiated clinical profile to date,\" RBC analysts said.</p><p>\"While the stock is unlikely to move significantly today, we came away confident in EWTX's opportunity to differentiate in HCM from CMIs,\" they added. HCM refers to hypertrophic cardiomyopathy, and CMI to cardiac myosin inhibitors.</p><p>RBC maintained its outperform rating and $59 price target.</p><p>Price: 41.26, Change: -3.25, Percent Change: -7.30</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Edgewise's EDG-7500 Mechanism Lends Confidence, RBC Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEdgewise's EDG-7500 Mechanism Lends Confidence, RBC Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-09-23 23:41</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Edgewise <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>' (EWTX) EDG-7500 mechanism reveal accounts for strong clinical showing, lending confidence ahead  of phase 3 trial design, RBC said in a Tuesday note.</p><p>Earlier, the company unveiled a differentiated mechanism of action of its cardiac sarcomere modulator EDG-7500.</p><p>The mechanism that targets the Regulatory Light Chain has shown in preclinical models to improve cardiac relaxation while preserving systolic function and cardiac reserve, Edgewise said.</p><p>\"We think the mechanism makes sense of the differentiated clinical profile to date,\" RBC analysts said.</p><p>\"While the stock is unlikely to move significantly today, we came away confident in EWTX's opportunity to differentiate in HCM from CMIs,\" they added. HCM refers to hypertrophic cardiomyopathy, and CMI to cardiac myosin inhibitors.</p><p>RBC maintained its outperform rating and $59 price target.</p><p>Price: 41.26, Change: -3.25, Percent Change: -7.30</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4539","symbol_name":"次新股","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2669876844","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2669876844","pubTimestamp":1790178065,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Edgewise Therapeutics'  EDG-7500 mechanism reveal accounts for strong clinical showing, lending confidence ahead  of phase 3 trial design, RBC said in a Tuesday note.Earlier, the company unveiled a differentiated mechanism of action of its cardiac sarcomere modulator EDG-7500.The mechanism that targets the Regulatory Light Chain has shown in preclinical models to improve cardiac relaxation while preserving systolic function and cardiac reserve, Edgewise said.\"We think the mechanism makes sense of the differentiated clinical profile to date,\" RBC analysts said.\"While the stock is unlikely to move significantly today, we came away confident in EWTX's opportunity to differentiate in HCM from CMIs,\" they added. HCM refers to hypertrophic cardiomyopathy, and CMI to cardiac myosin inhibitors.RBC maintained its outperform rating and $59 price target.Price: 41.26, Change: -3.25, Percent Change: -7.30","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4539":"次新股","BK4007":"制药","EWTX":"Edgewise Therapeutics, Inc."},"translate_title":"加拿大皇家银行表示，Edgewise 的 EDG-7500 机制带来信心","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EWTX":1},"content_text":"Edgewise Therapeutics' (EWTX) EDG-7500 mechanism reveal accounts for strong clinical showing, lending confidence ahead  of phase 3 trial design, RBC said in a Tuesday note.Earlier, the company unveiled a differentiated mechanism of action of its cardiac sarcomere modulator EDG-7500.The mechanism that targets the Regulatory Light Chain has shown in preclinical models to improve cardiac relaxation while preserving systolic function and cardiac reserve, Edgewise said.\"We think the mechanism makes sense of the differentiated clinical profile to date,\" RBC analysts said.\"While the stock is unlikely to move significantly today, we came away confident in EWTX's opportunity to differentiate in HCM from CMIs,\" they added. HCM refers to hypertrophic cardiomyopathy, and CMI to cardiac myosin inhibitors.RBC maintained its outperform rating and $59 price target.Price: 41.26, Change: -3.25, Percent Change: -7.30","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2669876844","isCrawlerRequest":true}